Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Erbitux (Cetuximab) - Important Safety Information from Merck Serono Ltd. as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
08/01/2014
Problem Or Issue:
Important Safety Information communication from Merck Serono Ltd. on the importance of establishing wild-type RAS (exons 2, 3 and 4 of KRAS and NRAS) before treatment with Erbitux (Cetuximab).
Important Safety Information - Erbitux (Cetuximab)
« Back
Date Printed: 19/05/2024